Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders

  title={Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders},
  author={Dario Siniscalco and Anna Sapone and Catia Giordano and Alessandra Cirillo and Laura de Magistris and Francesco Rossi and Alessio Fasano and James Jeffrey Bradstreet and Sabatino Maione and Nicola Antonucci},
  journal={Journal of Autism and Developmental Disorders},
Autistic disorders (ADs) are heterogeneous neurodevelopmental disorders arised by the interaction of genes and environmental factors. Dysfunctions in social interaction and communication skills, repetitive and stereotypic verbal and non-verbal behaviours are common features of ADs. There are no defined mechanisms of pathogenesis, rendering curative therapy very difficult. Indeed, the treatments for autism presently available can be divided into behavioural, nutritional and medical approaches… 
Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations
Dysregulation in the endocannabinoid system in a monocyte and macrophagic cellular model of autism has been demonstrated by showing that the mRNA and protein for CB2 receptor and EC enzymes were significantly dysregulated, further indicating the involvement of the EC system in autism-associated immunological disruptions.
Endocannabinoid system involvement in autism spectrum disorder: An overview with potential therapeutic applications
It has been demonstrated that ASD-related changes in the immune system involve alterations in monocyte and macrophage responses and pro-inflammatory cytokine up-regulation, opening the way for targeting this system with novel drugs for ASD.
Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious?
This mini-review article summarizes the current knowledge on the endocannabinoid system (ECS) and suggests that acetaminophen use in children increases the risk for ASD by interfering with the ECS.
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
An upregulation of CB2 receptors is found, associated with an activation of lymphocytes and changes in inflammation‐related genes, in DS patients, which may indirectly support the occurrence of a potential dysregulation of the endocannabinoid system in the brain.
Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder
A reduced eCB signalling was observed in autistic children and in the ASD animal model, and boosting 2-AG could ameliorate ASD-like phenotypes in animals, which suggested a novel approach to ASD treatment.
The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages
In vitro effects of GcMAF treatment on the transcriptionomics of the endocannabinoid system and expression of CB2R protein point to a potential nexus between endoc cannabinoidoids, vitamin D and its transporter proteins, and the immune dysregulations observed with autism.
Lower circulating endocannabinoid levels in children with autism spectrum disorder
Serum levels of AEA, OEA, and PEA were not significantly associated or correlated with age, gender, BMI, medications, and adaptive functioning of ASD participants, and in children with ASD, younger age and lower BMI tended to correlate with lower AEA levels.
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
Its non-psychoactive effect makes theCB2R a potential target for treating CNS disorders; however, a better understanding of the fundamental pharmacology of CB2R activation is essential for the design of novel therapeutic strategies.
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
This review describes the available data on the investigation of the presence of alterations of the EC system as well as the effects of its pharmacological manipulations in animal models of ASD-like behaviors.
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Preclinical and clinical data supporting CBD's potential as a treatment for the symptoms and comorbidities associated with ASD are reviewed, as well as discuss and provide information with the purpose of not trivializing the use of this drug.


Differential monocyte responses to TLR ligands in children with autism spectrum disorders
Plasma Cytokine Profiles in Subjects with High-Functioning Autism Spectrum Disorders
The results suggest that abnormal immune responses as assessed by multiplex analysis of cytokines may serve as one of the biological trait markers for ASD.
The cannabinoid system and immune modulation
It appears the immunocannabinoid system is involved in regulating the brain‐immune axis and might be exploited in future therapies for chronic diseases and immune deficiency.
Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders
The immune response in autism: a new frontier for autism research
This review will examine the status of the research linking the immune response with ASD and the potential that aberrant immune activity during vulnerable and critical periods of neurodevelopment could participate in the generation of neurological dysfunction characteristic of ASD.
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.
The results suggest that CB1 and CB2 can be considered as tissue-selective antigens of the central nervous system and immune system, respectively, and cannabinoids may exert specific receptor-mediated actions on the immune system through the CB2 receptor.
Elevated immune response in the brain of autistic patients
Endocannabinoids and the regulation of their levels in health and disease
Endocannabinoid levels appear to be transiently elevated as an adaptive reaction to re-establish normal homeostasis when this is acutely and pathologically perturbed.